重症肌无力
医学
托珠单抗
恶化
2019年冠状病毒病(COVID-19)
抗体
插管
人口
内科学
免疫学
胃肠病学
麻醉
疾病
传染病(医学专业)
环境卫生
作者
Pria Anand,Michaël C.C. Slama,Michelle Kaku,Charlene Ong,Anna M. Cervantes-Arslanian,Lan Zhou,William I. F. David,Amanda C. Guidon
摘要
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about its potential impact on patients with myasthenia gravis (MG).We studied the clinical course of COVID-19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies) between April 1, 2020-April 30-2020.Two patients required intubation for hypoxemic respiratory failure, whereas one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications.Our findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population.
科研通智能强力驱动
Strongly Powered by AbleSci AI